Search

Displaying results 6291 - 6300 of 10000 in total
  1. Drug

    Nitroaspirin

    go.drugbank.com/drugs/DB12445
    Investigational

    Nitroaspirin has been investigated for the treatment of Intermittent Claudication.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  2. Drug

    Guacetisal

    go.drugbank.com/drugs/DB13538
    Experimental

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  3. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication

  4. Drug

    Copper Cu-64

    go.drugbank.com/drugs/DB13980
    Approved

    [T604] It is used in molecular radiotherapy and positron emission tomography. … Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.

  5. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  6. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  7. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  8. Drug

    Epitizide

    go.drugbank.com/drugs/DB13989
    Experimental

    Epitizide is an agent, commonly found in combination [triamterene], used to produce diuresis.

  9. Drug

    P-nitrobiphenyl

    go.drugbank.com/drugs/DB12300
    ApprovedWithdrawn

    Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.

  10. Drug

    Lixudebart

    go.drugbank.com/drugs/DB19244
    Investigational

    Lixudebart, an investigational first-in-class monoclonal antibody, aims to reverse fibrosis.[L50833]